Patents by Inventor Yong-Chen Lu
Yong-Chen Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124935Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.Type: ApplicationFiled: December 27, 2023Publication date: April 18, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Yong-Chen Lu, Peter Fitzgerald, Zhili Zheng, Steven A. Rosenberg
-
Patent number: 11939365Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated human p53. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: September 17, 2018Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Drew C. Deniger, Steven A. Rosenberg, Anna Pasetto, Rami Yoseph, Winifred M. Lo, Yong-Chen Lu, Maria R. Parkhurst, Paul F. Robbins, Parisa Malekzadeh
-
Patent number: 11897933Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: June 11, 2021Date of Patent: February 13, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
-
Patent number: 11898207Abstract: Disclosed are methods of isolating paired T cell receptor (TCR) alpha and beta chain sequences, or an antigen-binding portion thereof. Also disclosed are methods of automatically identifying the TCR alpha and beta chain V segment sequences and CDR3 sequences of a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Methods of preparing a population of cells that express paired TCR alpha and beta chain sequences, or an antigen-binding portion thereof, are also disclosed. Isolated pairs of TCR alpha and beta chain sequences and isolated populations of cells prepared by the methods are also disclosed.Type: GrantFiled: March 28, 2018Date of Patent: February 13, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Yong-Chen Lu, Peter Fitzgerald, Zhili Zheng, Steven A. Rosenberg
-
Publication number: 20230406904Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: May 1, 2023Publication date: December 21, 2023Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Eric Tran, Yong-Chen Lu, Steven A. Rosenberg
-
Patent number: 11840561Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: December 3, 2021Date of Patent: December 12, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
-
Publication number: 20230203124Abstract: Disclosed are methods of isolating a TCR having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; selecting the autologous T cells; and isolating a nucleotide sequence that encodes the TCR from the selected autologous T cells, wherein the TCR has antigenic specificity for the mutated amino acid sequence encoded by the cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.Type: ApplicationFiled: December 29, 2022Publication date: June 29, 2023Applicant: The United States of America, a represented by the Secretary, Department of Health and Human ServiInventors: Eric Tran, Yong-Chen Lu, Paul F. Robbins, Steven A. Rosenberg
-
Patent number: 11667692Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: January 10, 2020Date of Patent: June 6, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Steven A. Rosenberg
-
Publication number: 20230026180Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: September 12, 2022Publication date: January 26, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rami Yoseph, Yong-Chen Lu, Gal Cafri, Steven A. Rosenberg
-
Patent number: 11466071Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: December 3, 2018Date of Patent: October 11, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rami Yoseph, Yong-Chen Lu, Gal Cafri, Steven A. Rosenberg
-
Publication number: 20220089677Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: December 3, 2021Publication date: March 24, 2022Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
-
Patent number: 11208456Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: April 2, 2020Date of Patent: December 28, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
-
Publication number: 20210300988Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: June 11, 2021Publication date: September 30, 2021Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
-
Publication number: 20210220457Abstract: Disclosed are methods of isolating T cells having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.Type: ApplicationFiled: March 8, 2021Publication date: July 22, 2021Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Paul F. Robbins, Steven A. Rosenberg
-
Patent number: 10973894Abstract: Disclosed are methods of isolating T cells having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation, the method comprising: identifying one or more genes in the nucleic acid of a cancer cell of a patient, each gene containing a cancer-specific mutation that encodes a mutated amino acid sequence; inducing autologous APCs of the patient to present the mutated amino acid sequence; co-culturing autologous T cells of the patient with the autologous APCs that present the mutated amino acid sequence; and selecting the autologous T cells. Also disclosed are related methods of preparing a population of cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.Type: GrantFiled: October 2, 2014Date of Patent: April 13, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Eric Tran, Yong-Chen Lu, Paul Robbins, Steven A. Rosenberg
-
Publication number: 20210079058Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: December 3, 2018Publication date: March 18, 2021Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rami Yoseph, Yong-Chen Lu, Gal Cafri, Steven A. Rosenberg
-
Publication number: 20200277352Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated human p53. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: September 17, 2018Publication date: September 3, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Drew C. Deniger, Steven A. Rosenberg, Anna Pasetto, Rami Yoseph, Winifred M. Lo, Yong-Chen Lu, Maria R. Parkhurst, Paul F. Robbins, Parisa Malekzadeh
-
Publication number: 20200247869Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: April 2, 2020Publication date: August 6, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
-
Publication number: 20200148739Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: ApplicationFiled: January 10, 2020Publication date: May 14, 2020Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Steven A. Rosenberg
-
Patent number: 10611816Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: July 31, 2017Date of Patent: April 7, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng